EP0099133A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Anti-cancer drugs comprising platinum complexes
Assignee: Yeda Research and Development Co Ltd
•
Filing: 1983-07-15
•
Granted: —
•
Expires: 2003-07-15
Abstract
Abstract @ There are provided anti-tumor agents comprising as active ingredient platinum complexed directly or via dextran-amine moieties to an anti-tumor immunoglobulin. These are prepared by reacting an anti-tumor immunoglobulin or such immunoglobulin coupled to a dextran-amine with a platinum salt. Immunoglobulins having a specific binding activity towards certain types of cancer cells can be used. Immunoglobulins specific for ovarian or testicular carcinoma or for renal adenocarcinoma complexed directly or via dextran-amine moieties with platinum are effective agents for the treatment of these malignancies.
Inventors
- 👤 Ruth Arnon
- 👤 Esther Hurwitz
- 👤 Rena Kashi
- 👤 Meir Wilchek
- 👤 Michael Sela
- 👤 Bilha Schechter
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-31 09:54
CPC Classifications
A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/68; A61K47/6835; A61K47/6883; A61K47/6801; A61K47/6803
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
16 words
An anti-tumor agent wherein platinum is complexed directly or via dextran-amine moiety to an anti-tumor immunoglobulin.
Claim 2
Dependent Claim
16 words
An anti-tumor agent wherein platinum is complexed directly or via dextran-amine moiety to an anti-tumor immunoglobulin.
Claim 3
Dependent Claim
19 words
An anti-tumor agent according to CLaim 1, being the product of complexing an anti-tumor immunoglobulin with a platinum salt.
Claim 4
Dependent Claim
17 words
An anti-tumor agent according to CLaim 2, wherein the platinum salt is K 2 PtCl 4 .
Claim 5
Dependent Claim
23 words
An anti-tumor agent according to CLaim 1, being the product of complexing of an immunoglobulin coupled to a dextran-amine with a platinum salt.
Claim 6
Dependent Claim
21 words
An anti-tumor agent according to CLaim 1, wherein the immunoglobulin is specific for ovarian or testicular carcinoma or for renal adenocarcinoma.
Claim 7
Dependent Claim
14 words
An anti-tumor agent according to CLaim 1 in the form of an injectable Liquid.
Claim 8
Dependent Claim
31 words
A process for preparing an anti-tumor immunoglobulin complex with platinum which comprises reacting a tumor- specific immunoglobulin with K 2 PtCl 4 in a reaction medium and removing the unreacted platinum.
Claim 9
Dependent Claim
31 words
A process for preparing an anti-tumor immunoglobulin complex with platinum which comprises reacting a tumor- specific immunoglobulin with K 2 PtCl 4 in a reaction medium and removing the unreacted platinum.
Claim 10
Dependent Claim
44 words
A process for preparing an anti-tumor agent wherein platinum is complexed via a dextran-amine to an anti-tumor immunoglobulin, which comprises oxidizing dextran, reacting same with ethylenediamine, reducing same, coupling same to a suitable immunoglobulin and reacting the thus formed product with a platinum salt.
Claim 11
Dependent Claim
44 words
A process for preparing an anti-tumor agent wherein platinum is complexed via a dextran-amine to an anti-tumor immunoglobulin, which comprises oxidizing dextran, reacting same with ethylenediamine, reducing same, coupling same to a suitable immunoglobulin and reacting the thus formed product with a platinum salt.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.